Next-Generation RNA Therapeutics Market Revenue and Forecast by 2033

28 Aug 2025

Share :

Table of Content

1. Next-Generation RNA Therapeutics Market Revenue and Trends 2025 to 2033 2. What are the Key Factors Influencing the Growth of the Next-Generation RNA Therapeutics Market? 3. Segment Insights 4. Regional Insights 5. Next-Generation RNA Therapeutics Market Coverage 6. Next-Generation RNA Therapeutics Market Key Players

Next-Generation RNA Therapeutics Market Revenue and Trends 2025 to 2033

The next-generation RNA therapeutics market is fueled by rising investment in RNA-based platforms, with expanding applications in oncology, rare diseases, and infectious conditions. The market's growth is driven by breakthroughs in mRNA technology, the expansion of clinical applications, and increasing demand for precision and personalized medicine.

What are the Key Factors Influencing the Growth of the Next-Generation RNA Therapeutics Market?

The market for next-generation RNA therapeutics is experiencing rapid growth due to the increased prevalence of chronic and genetic conditions, coupled with an urgent need for precision medicine, which is driving investments and advancements in the RNA solution space. Technological advances in RNA and mRNA, highlighted by the rapid development of COVID-19 vaccines, have boosted confidence in RNA platforms. The expanding scope of applications into oncology, rare diseases, and other infectious diseases is opening up new opportunities in the market. Emerging delivery systems, such as lipid nanoparticles (LNPs) and exosome-based carriers, have improved stability and targeted delivery, addressing previous issues.

Leading biopharmaceutical companies are focusing on developing novel RNA therapies through funding and partnerships. Rising collaborations between academic and research institutes, as well as government investments in drug discovery, are accelerating the RNA therapeutics pipeline. Increased patient acceptance and regulatory backing elevate the potential of RNA therapeutics as a transformative paradigm for next-generation healthcare.

Segment Insights

• By therapy type, the mRNA-based therapeutics segment led the market in 2024, holding the largest share due to the proven efficacy of mRNA vaccines. The rising scope of applications of mRNA vaccines, from infectious diseases to oncology, further supports segmental growth.
• By application, the infectious disease segment dominated the market in 2024, driven by the widespread success of mRNA vaccines in combating emerging infectious threats. The growing focus on pandemic preparedness ensures the long-term growth of the segment.
• By delivery mechanism, the lipid nanoparticles (LNPs) segment sustained dominance in the next-generation RNA therapeutics market in 2024 because of their superior stability, biocompatibility, and ability to be engineered for targeted delivery.
• By end-user, the biopharmaceutical companies segment contributed the largest share of the market, benefiting from their advanced research & development capabilities, partnerships, and investment capabilities to evolve the research, clinical development, and/or commercialization of RNA-based therapeutics. Their leading role in the research & development, as well as the commercialization, of RNA-based therapies makes them the largest end-users.

Regional Insights

North America continues to lead the next-generation RNA therapeutics market, thanks to its advanced biotechnology infrastructure, R&D investment, and regulatory support for innovative therapies. The success of mRNA vaccines, high demand for personalized medicine, and collaborations between leading pharmaceutical companies and research institutions bolster the region's leadership. There is a rising prevalence of chronic and infectious diseases, which further drives the demand for novel RNA therapeutics.

Asia Pacific is expected to experience rapid growth in the market for next-generation RNA therapeutics, driven by increasing government investments in biotechnology and healthcare infrastructure. Increased investments in RNA research and clinical trials are likely to contribute to market growth. The rising burden of cancer and infectious diseases across the region is creating immense opportunities for next-generation RNA therapeutics. Additionally, the rising development of vaccines supports regional market expansion.

Next-Generation RNA Therapeutics Market Coverage

Recent Development

• In August 2025, Axelyf, Inc. raised $2.6 million in seed funding, potentially reaching $4.1 million by fall, to advance its proprietary AXL lipid nanoparticle (LNP) delivery platform for RNA therapeutics. Led by Brunnur Ventures with support from Icelandic firms Omega ehf and Silfurberg ehf, the funding will drive development of AXL, which has shown superior in vivo gene editing potency, reduced immune response, and no liver toxicity, outperforming the current LP-01 benchmark used in Phase 3 trials. (Source: https://www.rna-seqblog.com)

Next-Generation RNA Therapeutics Market Key Players

• Alnylam Pharmaceuticals
• Arcturus Therapeutics
• Arrowhead Pharmaceuticals
• AstraZeneca
• BioNTech SE
• Chimeron Bio
• CureVac AG
• eTheRNA Immunotherapies
• Gilead Sciences
• Ionis Pharmaceuticals
• Moderna Therapeutics
• Pfizer
• Replicate Bioscience
• Roche
• Sarepta Therapeutics
• Silence Therapeutics
• Takeda
• Translate Bio (Sanofi)
• Vaccibody (Nykode Therapeutics)
• Vertex Pharmaceuticals

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6655

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344